Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.

Also called NCT01907854

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 407 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01907854
  • EudraCT 2012-004931-22
  • CTRI CTRI/2014/05/004623
Other papers using this trial's data
  • Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial Diabetes, obesity & metabolism, 2016-12 DOI, PubMed 27381275, PMC5129465 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Hungary, India, Israel, Puerto Rico, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01907854. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2015-06-15 (actual). Results posted on 2016-07-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
Acronym
LIRA-SWITCH™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
sitagliptin
Intervention (Drug)
placebo
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01907854
Content hash
94c72548f175c9f108ef01c4c27c377179bfa96ef541cab95dc131273e950a9d